Which statement is true regarding the administration of metoprolol in a patient with ST-elevation myocardial infarction?

In the context of administering metoprolol during an ST-elevation myocardial infarction (STEMI), it is essential to understand the timing and clinical considerations for beta-blocker use. The choice regarding when to administer metoprolol is primarily influenced by the patient's hemodynamic stability and risk factors for complications.

The statement that beta-blockers should not be given because they increase the risk of cardiogenic shock is aligned with concerns present in specific patient populations. In the early hours of a STEMI, particularly if the patient exhibits signs of significant left ventricular dysfunction or if they present with hypotension, initiating beta-blocker therapy can worsen hemodynamic status and potentially lead to cardiogenic shock. In this acute setting, it is critical to monitor the patient's blood pressure, heart rate, and overall clinical condition to ensure the safe administration of metoprolol.

Conversely, while metoprolol is beneficial in reducing mortality and morbidity in post-acute management of myocardial infarction and may help in controlling heart rate and myocardial oxygen demand, its initiation must be timed correctly. Beta-blockers are generally recommended once the patient is stable, especially if they don't present with signs that would contraindicate their use, such as acute heart failure or significant br